Surrozen, Inc.
171 Oyster Point Boulevard
Suite 400
South San Francisco
California
94080
United States
Tel: 650-475-2820
Website: http://surrozen.com/
About Surrozen, Inc.
Repair. Restore. Renew
Surrozen is a biotechnology company focused on discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway. Surrozen is at pre-clinical stage, and anticipates its first clinical trials will be underway in 2022. Surrozen (SRZN) became publicly traded in August of 2021.
Culture
Our inclusive and pioneering culture creates a sense of belonging, impact, adventure and fun. Join us and Collaborate, Lead, Innovate Motivate and be Brave, Open and Nurturing at Surrozen!
Total Rewards
Surrozen offers a competitive total rewards package that includes:
- Health and welfare benefits
- Generous vacation, sick leave, and company paid holidays
- 401k match
- Company sponsored events, adventures and weekly lunches
- Bring your dog to work Fridays
Craig Parker is the Chief Executive Officer at Surrozen. Their research in the Wnt pathway and proteins identified these are critical to maintaining tissues in our body and are found in tissues as diverse as the lung, intestine, liver, sensory hair cells, and the eye.
New Company Values
A committee of Surrozen employees put their heads together and came up with our new company values. In every project we take on these 7 keys words are at the forefront. CLIMB ON!!!
49 articles with Surrozen, Inc.
-
Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference - Jan 04, 2023
1/4/2023
Surrozen, Inc., a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, will present on January 12, 2023 at 7:30 a.m. Pacific time at the 41st Annual J.P. Morgan Healthcare Conference.
-
Surrozen announced it paused its Phase I study in Crohn’s disease and ulcerative colitis as several healthy participants showed increased levels of liver enzymes.
-
Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week
10/10/2022
Surrozen, Inc. today announced the presentation of data supporting the continued development of its lead therapeutic programs at United European Gastroenterology Week (UEGW), being held Oct. 8-11 in Vienna.
-
Surrozen announced Thursday it has partnered with Boehringer Ingelheim to research and develop a therapeutic for the treatment of retinal diseases.
-
Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases
10/6/2022
Surrozen, Inc. (Nasdaq: SRZN) announced today that it has entered into a collaboration and license agreement with Boehringer Ingelheim to research and develop SZN-413 for the treatment of retinal diseases.
-
Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy
9/26/2022
Surrozen, Inc. announced today the publication of an article by Surrozen scientists in the journal Translational Vision Science and Technology.
-
Surrozen Reports Second Quarter 2022 Financial Results
8/11/2022
Surrozen, Inc. today reported financial results for the second quarter of 2022 and provided a corporate update.
-
Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis
6/13/2022
Surrozen, Inc. today announced that the first subject has been dosed in its two-part Phase 1 clinical trial for SZN-043 which is in development for the potential treatment of severe alcoholic hepatitis.
-
Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)
5/24/2022
Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced the presentation of data supporting the continued development of its lead therapeutic programs at Digestive Disease Week (DDW) 2022 in San Diego.
-
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
-
Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis
5/18/2022
Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a clinical-stage company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that the first subject has been dosed in its three-part Phase 1 clinical trial.
-
Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of IBD
5/16/2022
Surrozen, Inc. announced the publication of an article by Surrozen scientists in the journal Cellular and Molecular Gastroenterology and Hepatology.
-
Surrozen Reports First Quarter 2022 Financial Results
5/11/2022
Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today reported financial results for the first quarter of 2022 and provided a corporate update.
-
Surrozen to Present at the BofA Securities 2022 Healthcare Conference
5/5/2022
Surrozen, Inc. today announced that Craig Parker, President and Chief Executive Officer, will present at the BofA Securities 2022 Healthcare Conference at 4 p.m. PT on Wednesday, May 11.
-
Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
5/2/2022
Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, announced today that a poster supporting the potential of SZN-413 for the treatment of diabetic retinopathy was presented on May 1 at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Denver.
-
Surrozen Reports Fourth Quarter and Full Year 2021 Financial ResultsOn Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326 and SZN-043 in the Third Quarter of 2022
3/24/2022
Surrozen, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.
-
Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline
1/10/2022
Surrozen, Inc., a company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, announced key development goals and acceleration of its research pipeline as the company transitions to a clinical-stage biotechnology company.
-
Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
1/5/2022
Surrozen, Inc., a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, will present virtually on January 13, 2022 at 9 a.m. ET, at the 40th J.P. Morgan Healthcare Conference.
-
Surrozen's ethos is “CLIMB ON”. This catchy and focus-appropriate acronym stands for Collaborate, Lead, Innovate, Motivate and be Brave, Open and Nurturing.
-
Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference
11/15/2021
Surrozen, Inc. today announced that Craig Parker, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference at 10:00 a.m. ET on Monday, November 22.